AcquisitionOther

Supernus Pharmaceuticals, Inc. acquired Sage Therapeutics, Inc.

Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.

Deal tape row

Supernus Pharmaceuticals, Inc. -> Sage Therapeutics, Inc. · $8.50 per share plus up to $3.50 contingent value right per share

Strengthens neuropsychiatric portfolio with innovative commercial product ZURZUVAE and novel CNS discovery platform.